NEA Management Company, LLC

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), NEA Management Company, LLC reported 42 stock positions worth $1.8 billion. Its top holding was Arcellx (ACLX) at 17.0% of the portfolio, followed by Tempus AI Class A (TEM, 16.6%) and Verona Pharma (VRNA, 8.8%). Compared with Q2 2024, it opened 4 new positions, sold out of 3, added to 2 and reduced 2. The biggest buy was a new position in MBX Biosciences (MBX) and the biggest sale an exit from Regulus Therapeutics (RGLS).

Most Recent 13F
Q2 2026
Location
TIMONIUM, MD
CIK
0001512848
Portfolio Value
$1.8B (Q3 2024)
SEC Filing
0001012975-24-000496 ↗ filed Nov 14, 2024

Holdings Value

0$500.0M$1.0B$1.5B$2.0B Q1 2024: $1.6B Q1 2024 Q2 2024: $1.3B Q2 2024 Q3 2024: $1.8B $1.8B Q3 2024 Q4 2024: $1.8B Q4 2024 Q1 2025: $1.3B Q1 2025 Q2 2025: $1.3B Q2 2025 Q3 2025: $1.8B Q3 2025 Q4 2025: $2.0B Q4 2025 Q1 2026: $1.8B Q1 2026 Q2 2026: $1.6B Q2 2026

Holdings 42 stocks · $1.8B
ACLX Arcellx Inc. 17.04% 3,745,262 $312.8M No change
TEM Tempus AI Inc. Class A 16.61% 5,385,979 $304.8M Add +17.8%
VRNA Verona Pharma Ltd. 8.75% 5,584,753 $160.7M No change
RYTM Rhythm Pharmaceuticals Inc. 8.31% 2,909,956 $152.5M No change
SVRA Savara Inc. 5.65% 24,471,264 $103.8M No change
COUR Coursera Inc. 5.57% 12,867,769 $102.2M No change
MBX MBX Biosciences Inc. 5.12% 3,614,486 $93.9M New
CRSP Crispr Therapeutics AG 4.06% 1,587,854 $74.6M No change
NN Nextnav Inc. 3.34% 8,189,156 $61.3M No change
ZBIO Zenas Biopharma Inc. 2.41% 2,613,948 $44.2M New
GLUE Monte Rosa Therapeutics Inc. 2.22% 7,692,298 $40.8M No change
TRVI Trevi Therapeutics Inc. 2.07% 11,370,376 $38.0M No change
KRRO Korro Bio Inc. 1.99% 1,090,793 $36.5M No change
PHAT Phathom Pharmaceuticals Inc. 1.93% 1,960,169 $35.4M No change
AUPH Aurinia Pharmaceuticals Inc. 1.59% 3,969,834 $29.1M No change
CVRX CVRX Inc. 1.14% 2,370,542 $20.9M No change
BDTX Black Diamond Therapeutics I 1.05% 4,448,757 $19.4M No change
CELC Celcuity Inc. 1.02% 1,250,001 $18.6M No change
GOSS Gossamer Bio Inc. 0.98% 18,093,034 $17.9M No change
ADAPY Adaptimmune Therapeutics-ADR 0.88% 17,079,778 $16.2M No change
NKTX Nkarta Inc. 0.88% 3,568,781 $16.1M No change
ORIC Oric Pharmaceuticals Inc. 0.84% 1,500,000 $15.4M No change
NEUE Neuehealth Inc. 0.78% 2,726,917 $14.2M No change
INZY Inozyme Pharma Inc. 0.69% 2,437,689 $12.7M No change
GERN Geron Corp. 0.69% 2,776,409 $12.6M No change
BZFD Buzzfeed Inc. 0.56% 3,833,473 $10.2M No change
RGLS Regulus Therapeutics Inc. 0.55% 6,467,802 $10.2M New
XFOR X4 Pharmaceuticals Inc. 0.55% 14,986,793 $10.0M No change
CSBR Champions Oncology Inc. 0.45% 1,713,720 $8.3M No change
RENEO PHARMACEUTICALS INC 0.44% 4,785,494 $8.1M No change
DM Desktop Metal Inc. Class A 0.37% 1,439,892 $6.7M No change
SGMT Sagimet Biosciences Inc. Class A 0.30% 2,000,275 $5.5M No change
SYBX Synlogic Inc. 0.24% 2,922,772 $4.4M No change
ALLK Allakos LLC 0.22% 6,147,260 $4.0M No change
LXRX Lexicon Pharmaceuticals Inc. 0.20% 2,382,286 $3.7M No change
MRKR Marker Therapeutics Inc. 0.16% 1,071,428 $3.0M No change
IVA Inventiva SA - ADR 0.15% 1,462,586 $2.7M No change
AFMDQ Affimed NV 0.08% 442,648 $1.5M Reduce 0.0%
IKENA ONCOLOGY INC 0.06% 600,063 $1.0M Add +5.3%
SNTI Senti Biosciences Inc. 0.05% 442,615 $1.0M New
UP Wheels Up Experience Inc. 0.01% 106,125 $257K No change
MYND Mynd.ai Inc. 0.01% 206,208 $165K Reduce -94.3%

Portfolio Sells Q2 2024 → Q3 2024
RGLS Regulus Therapeutics Inc. Sold out 0.00% −0.87
MYND Mynd.ai Inc. Reduce -94.3% 0.01% −0.75
TUYA Tuya Inc. Sold out 0.00% −0.42
AFMDQ Affimed NV Reduce 0.0% 0.08% −0.10
SNTI Senti Biosciences Inc. Sold out 0.00% −0.09

Portfolio Buys Q2 2024 → Q3 2024
MBX MBX Biosciences Inc. New 5.12% +5.12
TEM Tempus AI Inc. Class A Add +17.8% 16.61% +4.57
ZBIO Zenas Biopharma Inc. New 2.41% +2.41
RGLS Regulus Therapeutics Inc. New 0.55% +0.55
SNTI Senti Biosciences Inc. New 0.05% +0.05
IKENA ONCOLOGY INC Add +5.3% 0.06% −0.01

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 26$1.6BTRVI, MBX, GLUE, CELC, SGP
Q1 2026 26$1.8BACLX, CELC, SGP, TRVI, SVRA
Q4 2025 27$2.0BCELC, RYTM, ACLX, TRVI, SVRA
Q3 2025 29$1.8BRYTM, ACLX, VRNA, COUR, TRVI
Q2 2025 32$1.3BACLX, VRNA, RYTM, COUR, CRSP
Q1 2025 37$1.3BACLX, VRNA, RYTM, TEM, COUR
Q4 2024 41$1.8BACLX, VRNA, TEM, RYTM, NN
Q3 2024 42$1.8BACLX, TEM, VRNA, RYTM, SVRA
Q2 2024 41$1.3BACLX, TEM, RYTM, SVRA, COUR
Q1 2024 44$1.6BACLX, CRSP, RYTM, SVRA, COUR